There have been several reports early today about products that have not fared well at their last review point in late clinical trials. As a result, it is likely that these will now be dropped from consideration for further development.
As reported in the Pharma Strategy blog, Roche and Biogen Idec's ocrelizumab anti-CD20 Mab for treatment of rheumatoid arthritis and Lupus has been discontinued as safety testing revealed signifcant potential of facilitating opportunistic infections - some of which were fatal. Not really a good selling point for most pharmaceuticals.
AstraZeneca confirmed that its cediramib anti-VEGF inhibitor (aka Recentin) intended for treatment of colorectal cancer failed to meet its clinical endpoint in a phase III (Horizon III) trial. The molecule did not perform better against Roche's Avastin (bevacizumab) in comparable combo chemotherapy study. Oops! You can read more in the Pharma Strategy blog or in PharmaGossip.
Posted by Bruce Lehr March 8th, 2010.